Literature DB >> 12029439

Expression of c-kit protein in proliferative lesions of human breast: sexual difference and close association with phosphotyrosine status.

Y Tsuura1, T Suzuki, K Honma, M Sano.   

Abstract

PURPOSE: The c-kit gene which codes transmembrane tyrosine kinase receptor protein plays an important role in several types of normal and/or neoplastic human tissues. We examined the expression patterns of c-kit protein in proliferative lesions of human breast tissues in both sexes.
METHODS: The localization of c-kit protein was examined immunohistochemically in human breast, consisting of 366 normal tissue, 156 benign lesions (fibroadenoma, fibrocystic change, intraductal papilloma, benign phyllodes tumor, and gynecomastia), 13 borderline diseases (atypical ductal hyperplasia, atypical lobular hyperplasia, and borderline malignant phyllodes tumor), and 197 malignant lesions (non-invasive and/or invasive ductal carcinoma and malignant phyllodes tumor).
RESULTS: In normal tissues and benign proliferative lesions, c-kit product was consistently detected on epithelial cell membranes and/or cytoplasms regardless of gender difference. In contrast, we failed to find c-kit product in female borderline epithelial lesions, including atypical lobular hyperplasia, or in female malignant lesions, except for two carcinomas. In situ hybridization analysis of c-kit mRNA in female tissues gave results comparable to those obtained by immunohistochemistry. On the other hand, c-kit product was consistently detected in male benign and malignant proliferative lesions. Apart from the female breast carcinomas which lacked c-kit, c-kit expression was almost always accompanied by positivity for phosphotyrosine in the breast tissues examined, suggesting possible phosphorylation of tyrosine residues of the c-kit receptor protein.
CONCLUSIONS: Loss of c-kit product was related to malignant transformation in female breast, but not in the case of male breast. We suggest that the oncogenesis pathway of breast epithelium is different between males and females in terms of c-kit expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12029439     DOI: 10.1007/s00432-002-0329-2

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  7 in total

1.  Screening of the c-kit gene missense mutation in invasive ductal carcinoma of breast among north Indian population.

Authors:  Syed Rizwan Hussain; Sunil G Babu; Syed Tasleem Raza; Pradyumn Singh; Faisal Ahmed; Hena Naqvi; Farzana Mahdi
Journal:  Mol Biol Rep       Date:  2012-06-24       Impact factor: 2.316

2.  Expression of C-KIT, CD24, CD44s, and COX2 in benign and non-invasive apocrine lesions of the breast.

Authors:  Trine Tramm; Jee-Yeon Kim; Sebastian Leibl; Farid Moinfar; Fattaneh A Tavassoli
Journal:  Virchows Arch       Date:  2016-06-10       Impact factor: 4.064

3.  Expression of c-kit proto-oncogene product in breast cancer tissues.

Authors:  Aydan Eroğlu; Aliye Sari
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

4.  Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib.

Authors:  Kiana Keyvanjah; Samuel E DePrimo; Charles S Harmon; Xin Huang; Kenneth A Kern; William Carley
Journal:  J Transl Med       Date:  2012-08-16       Impact factor: 5.531

5.  A loss of c-kit expression is associated with an advanced stage and poor prognosis in breast cancer.

Authors:  S Tsutsui; K Yasuda; K Suzuki; H Takeuchi; T Nishizaki; H Higashi; S Era
Journal:  Br J Cancer       Date:  2006-05-23       Impact factor: 7.640

6.  Quantitative immunohistochemical expression of c Kit in breast carcinomas is predictive of patients' outcome.

Authors:  C Charpin; S Giusiano; S Charfi; V Secq; S Carpentier; L Andrac; M-N Lavaut; C Allasia; P Bonnier; S Garcia
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

7.  Expression of c-kit protein in cancer vs. normal breast tissue.

Authors:  Abdolhassan Talaiezadeh; Seyed Nematollah Jazayeri; Jamal Nateghi
Journal:  Contemp Oncol (Pozn)       Date:  2012-09-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.